高级搜索

CXCR1/CXCR2受体拮抗剂—G31P抑制前列腺癌血管新生的体内实验

刘欣, 戴晓冬, 李星云, 王晓丽, 李芳

刘欣, 戴晓冬, 李星云, 王晓丽, 李芳. CXCR1/CXCR2受体拮抗剂—G31P抑制前列腺癌血管新生的体内实验[J]. 肿瘤防治研究, 2012, 39(07): 784-786. DOI: 10.3971/j.issn.1000-8578.2012.07.006
引用本文: 刘欣, 戴晓冬, 李星云, 王晓丽, 李芳. CXCR1/CXCR2受体拮抗剂—G31P抑制前列腺癌血管新生的体内实验[J]. 肿瘤防治研究, 2012, 39(07): 784-786. DOI: 10.3971/j.issn.1000-8578.2012.07.006
Liu Xin, Dai Xiaodong, Li Xingyun, Wang Xiaoli, Li Fang. Inhibition of G31P:Chemokine Receptor CXCR1/CXCR2 Antagonist,in Angiogenesis of Human Prostate Cancer Cells in vivo[J]. Cancer Research on Prevention and Treatment, 2012, 39(07): 784-786. DOI: 10.3971/j.issn.1000-8578.2012.07.006
Citation: Liu Xin, Dai Xiaodong, Li Xingyun, Wang Xiaoli, Li Fang. Inhibition of G31P:Chemokine Receptor CXCR1/CXCR2 Antagonist,in Angiogenesis of Human Prostate Cancer Cells in vivo[J]. Cancer Research on Prevention and Treatment, 2012, 39(07): 784-786. DOI: 10.3971/j.issn.1000-8578.2012.07.006

CXCR1/CXCR2受体拮抗剂—G31P抑制前列腺癌血管新生的体内实验

详细信息
    作者简介:

    刘欣 (1976-),女,硕士,讲师,主要从事趋化因子的研究

    通讯作者:

    李芳,E-mail:lifang16@hotmail.com

  • 中图分类号: R737.25

Inhibition of G31P:Chemokine Receptor CXCR1/CXCR2 Antagonist,in Angiogenesis of Human Prostate Cancer Cells in vivo

  • 摘要: 目的 探讨G31P(CXCR1/CXCR2受体拮抗剂)对人前列腺癌PC-3细胞的体内血管新生的抑制作用。方法建立体内绿色荧光蛋白(GFP)标记的人雄激素非依赖性前列腺癌细胞PC-3的裸鼠原位移植瘤模型,观察G31P对裸鼠前列腺原位移植瘤血管新生的影响。结果与对照组(1.26±0.46)相比,G31P处理组明显抑制前列腺肿瘤的血管新生(0.49±0.12,P<0.05),与对照组相比,G31P处理组VEGF (P<0.01)和NF-κB(P<0.01)的表达具有统计学意义(免疫组织化学法)。结论在裸鼠原位移植瘤模型中G31P对人雄激素非依赖性前列腺癌的血管新生有明显抑制作用。

     

    Abstract: Objective To investigate the inhibition of G31P on the angiogenesis of the prostate cancer PC-3 cell in vivo. Methods The effect of G31P on angiogenesis of human prostate tumor of nude mice were observed in nude mice by building a human androgen-independent prostate cancer PC-3 (GFP-labeled) orthotopic transplantation tumor cells model. Results The tumor angiogenesis of G31P treated group (1.26±0.46)was significantly reduced (0.49±0.12,P<0.05) compared with the control group.VEGF(P<0.01)and NF-κB(P<0.01)expression of G31P treated groupwas significantly reduced (immunohistochemistry) compared with the control group. Conclusion G31P could inhibit the angiogenesis of the prostate cancer PC-3 cell in vivo.

     

  • [1] Vicari AP,Caux C.Chemokines in cancer[J].Cytokine Growth Factor Rev,2002,13(2):143-54.
    [2] O′Hayer KM,Brady DC,Counter CM.ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis[J].Carcinogenesis,2009,30 (11):1841-7.
    [3] Wang J.Progress of the application of vascular endothelial growth factor and its receptor in anti-tumortherapy[J].Zhongguo Yi Yao Gong Ye Za Zhi,2007,38(5):381-6.[王娟.血管内皮生长因子及其受体在抗肿瘤治疗应用的研究进展[J].中国医药工业杂志,2007,38(5):381-6.]
    [4] Gaurnier-Hausser A,Tuszynski GP.The immunomodulatory role of angiocidin,a novel angiogenesis inhibitor [J].Curr Pharm Des,2009,15(17),1937-48.
    [5] Heidemann J,Ogawa H,Dwinell MB,et al.Angiogeneic effects of interleukin 8 (CXCL8) in humanintestinalmicrovascular endothelial calls are mediated by CXCR2 [J].J Biol Chem,2003,278 (10):8508-15.
    [6] Addison CL,Daniel TO,Burdick MD,et al.The CXC chemokine receptor 2,CXCR2,is the putative receptor for ELR+CXC chemokine-induced angiogenic activity [J].J Immunol,2000,165 (9):5269-77.
计量
  • 文章访问数:  2140
  • HTML全文浏览量:  16
  • PDF下载量:  665
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-08-31
  • 修回日期:  2011-12-27
  • 刊出日期:  2012-07-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭